Aurenar is addressing life-threatening and costly secondary complications that result from hemorrhagic stroke (e.g. vasospasm, hydrocephalus, infection). Following the initial repair of a brain hemorrhage, stroke patients are held in a neurocritical care unit to monitor and treat serious secondary complications, requiring expensive hospital stays ranging from weeks to months. 

Aurenar has already performed an NIH-funded randomized controlled clinical study (N=24) with exciting results that validate its novel ear stimulation technology. Clinical results demonstrate large and statistically significant improvements in patient outcomes, reduction of hospital stays, and reduction in overall costs for patients that received the novel therapy vs patients that did not. 

Aurenar is a unique seed-stage startup that is launching from a solid foundation—supportive clinical data, an IP portfolio that includes 13 granted patents, and comprehensive development, regulatory, and go-to-market strategies. Aurenar is led by co-founding neurosurgeon and serial entrepreneur, Dr. Eric Leuthardt, and supported by a seasoned team that blends business, engineering, regulatory, and clinical trial expertise. Aurenar is currently raising a seed round to develop its product, V-Link, under FDA-required design controls and perform required validation and safety testing necessary to initiate a final pivotal clinical trial. Two planned follow-on rounds will support the pivotal clinical trial and commercial launch.

Aurenar is a unique seed-stage neurotechnology company with impactful accomplishments that surpass most series-A stage companies—specifically:

Aurenar’s NIH-funded clinical study was conducted with non-dilutive funding and demonstrated statistically significant improvements in stroke patient outcomes while simultaneously reducing hospital stays and medical costs.  Beyond the benefit of DE-RISKED TECHNOLOGY, these positive results provide the basis for Aurenar’s VALIDATED BUSINESS MODEL, demonstrating medical and cost benefits to patients, hospitals, and insurers.  Importantly, early completion of this study results in an ACCELERATED PATH TO MARKET by eliminating years of time and millions of dollars otherwise required for an equivalent future pilot study.

Additional value-adding achievements include:

Aurenar is ahead of the game with a team of experts who have devised integrated plans spanning product development, regulatory, clinical, and go-to-market strategy.  Collectively, these valuable early achievements have Aurenar positioned for rapid success.